Tuesday - March 03, 2026

Category Archives: Science

Multiple Sclerosis Treatment Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Multiple Myeloma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Multiple Myeloma Pipeline Insights 2026” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Metastatic Melanoma Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Melanoma Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and … Continue reading →

Metastatic Breast Cancer Clinical Trial Pipeline Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Metastatic Breast Cancer Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Non-Alcoholic Steatohepatitis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Non-Alcoholic Steatohepatitis (NASH) pipeline landscape. It covers the Non-Alcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Myelodysplastic Syndrome Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insights 2026” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Living Forever – AI Accepted into NVIDIA Inception Program to Advance Interactive Family Legacy Platform

AI startup building interactive video avatars that preserve living people’s personalities, voices, and stories gains access to NVIDIA’s global AI ecosystem ATLANTA, GA – February 27, 2026 – Living Forever — AI, an Atlanta-based startup building fully interactive video AI digital … Continue reading →

Melanoma Treatment Pipeline Shows Strong Momentum as 150+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Melanoma Pipeline Insights 2026” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline … Continue reading →